Wave Life Sciences Ltd.

WVE

Held by 6 specialist biotech funds

High Convergence

6 funds opened new positions. Next phase2 readout (WVE-N531): Jun 2026. Short interest: 11.6% of float.

BiotechnologyCEO: Paul BolnoIPO: 2015Website ↗

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.

Catalysts

Phase 3NegativeQ4 2019WVE-210201 (suvodirsen)Duchenne Muscular DystrophyNCT03907072

Primary: Change From Baseline in Dystrophin Level (% Normal Dystrophin) (Day 1 to Week 12, Week 22, or Week 46)Enrollment:6/6Sites: 22RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ2 2021WVE-120102Huntington DiseaseNCT04617860

Primary: Safety: Number of Patients With Treatment-emergent Adverse Events (TEAEs) (Day 1 to Study Termination (maximum of 12 monthly doses))Enrollment:36/36Sites: 20NA, TREATMENT

Phase 2NegativeQ2 2021WVE-120101Huntington DiseaseNCT04617847

Primary: Safety: Number of Patients With Treatment-emergent AEs (TEAEs) (First dose received (Day 1) through the Study Termination visit (maximum of 45 weeks of treatment))Enrollment:27/27Sites: 18NA, TREATMENT

Phase 2NegativeQ2 2021WVE-120102Huntington's DiseaseNCT03225846

Primary: Safety: Number of Patients With Treatment-emergent Adverse Events (TEAEs) (Day 1 to end of study (up to Day 182 [32 mg cohort]/ Day 210 [all other cohorts]))Enrollment:88/88Sites: 26RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ2 2021WVE-120101Huntington's DiseaseNCT03225833

Phase 2NegativeQ2 2023WVE-004ALS, FTDNCT04931862

Phase 2NegativeQ2 2023WVE-004ALS, FTDNCT05683860

Phase 2Q2 2024SAD: 30mg WVE-003Huntington DiseaseNCT05032196

Phase 2Q2 2026WVE-N531Duchenne Muscular DystrophyNCT04906460

Primary: Part A: Safety: Proportion of patients with adverse events (AEs) (Day 1 (initial dose) up to 24 weeks after the last dose of Part A)Enrollment:Target 26Sites: 5NA, TREATMENT

Phase 2Q3 2026WVE-006Alpha-1 Antitrypsin DeficiencyNCT06405633

Primary: The proportion of participants with adverse events (Up to 36 Weeks)Enrollment:Target 24Sites: 9NON_RANDOMIZED, TREATMENT

Phase 2Q4 2027WVE-007Overweight and ObesityNCT06842186

Phase 2Q1 2029WVE-N531Duchenne Muscular DystrophyNCT07209332

Wave Life Sciences Ltd.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Recent Insider Activity

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research